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Abstract: In this year-long, prospective observational study, sociodemographic, clinical, 
and functional characteristics were assessed in outpatients with schizophrenia from Australia, 
  Mexico, Romania, and Taiwan who were switched from their primary oral antipsychotic to 
another oral or depot antipsychotic at study entry because of physician-perceived   nonadherence 
risks. Patients (N = 406) rated their quality of life and functioning level as low. Few patients 
(10.6%, 43/406) were switched to depot antipsychotics, with country-specific differences 
(P , 0.001). Although illness severity was similar between subgroups, the depot switch   subgroup 
had: a documented history of nonadherence (32.6% versus oral: 4.7%); recent alcohol (48.8% 
versus 23.2%; P , 0.001) or illicit drug use (16.3% versus 5.0%; P = 0.010); recent depot 
antipsychotic (20.7% versus 7.5%; P = 0.030) and mood stabilizer use (51.7% versus 26.3%; 
P = 0.008); poorer attitudes towards medication (P = 0.004); and poorer illness   awareness 
(P = 0.041). Findings indicate that even when a risk of nonadherence has been identified, 
few patients with schizophrenia receive depot antipsychotics, despite being prime candidates 
for depot therapy. Findings suggest physicians may select depot therapy based on previous 
  nonadherence, substance use, recent depot antipsychotic and mood stabilizer use, poor attitudes 
towards medications, and poor illness awareness.
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Nonadherence with antipsychotic medication is a common problem for patients with 
schizophrenia and is a reliable predictor for relapse, hospitalization, and poor   long-term 
functional outcomes.1–3 How the physician responds to and identifies effective   treatment 
strategies for these patients can be challenging, as medication nonadherence is a 
dynamic rather than a static situation. Patients may discontinue their antipsychotic 
medication for various and complex reasons including insufficient efficacy or concerns 
around tolerability of the medication.1 In addition, patients with a history of   medication 
nonadherence, or who have poor insight into having a mental illness or a negative 
attitude to their medication may be at increased risk of nonadherence.4,5
Most treatment guidelines recommend that depot antipsychotics be considered as 
a treatment option for nonadherent patients who are at risk of relapse or who relapse 
frequently.6–10 Despite these recommendations, the use of depot antipsychotics varies 
among countries and regions,11–13 and in some countries, such as the United States, 
few nonadherent patients appear to be treated with depot antipsychotics.4,14
Several retrospective claims database studies and retrospective analyses of 
  prospective observational studies involved examinations of the sociodemographic, 
clinical, and functional characteristics of patients switched to, or treated with, depot 
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antipsychotics.4,15–18 Factors   identified in these studies that 
may influence whether patients are switched to depot or oral 
antipsychotics include gender, age, alcohol and/or illicit drug 
use, treatment pattern, and clinical profile. These retrospec-
tive analyses are useful for identifying factors that may influ-
ence treatment decisions in routine clinical practice. However, 
prospective, naturalistic studies of nonadherent patients with 
schizophrenia are needed to confirm the findings of these 
retrospective analyses.
In this one-year, prospective, noninterventional, obser-
vational study, physicians in Australia, Mexico, Romania, 
and Taiwan treating outpatients with schizophrenia assessed 
their patients’ risk of nonadherence. Patients who were 
considered to be at risk of nonadherence and who were 
switched from their primary oral antipsychotic medication 
to another oral or a depot antipsychotic at study entry, at 
their physician’s discretion, were included in this study. At 
study entry, the patient’s sociodemographics, psychiatric 
illness and treatment history, previous resource utiliza-
tion, and patient-reported medication adherence were col-
lected, and the patient’s illness severity, attitude to their 
medication(s), insight into their illness, and quality of life 
were assessed.
The aim of this report was to describe the sociodemo-
graphic, clinical, and functional characteristics of patients at 
risk of nonadherence, and to compare these characteristics 
of patients who were switched to a depot antipsychotic with 
patients who were switched to another oral antipsychotic at 
study entry.
Methods
study design
This was a one-year, prospective, multicenter, nonin-
terventional, observational study of outpatients with 
schizophrenia who required a change in their primary 
antipsychotic   treatment because of a physician-perceived 
risk of   nonadherence. The primary objective of this study 
was to establish the time to   all-cause treatment discontinua-
tion of the antipsychotic   initiated at study entry, which will 
be reported in a   subsequent report; however, this report is 
focused on the patients’   sociodemographic, clinical, and 
functional characteristics at study entry. The study was con-
ducted from April 2007 to July 2009 in 31 clinical practice 
sites located in Australia (10), Mexico (3), Romania (14), 
and Taiwan (4).
All patients provided voluntary, written informed consent 
for the use of their personal health information collected 
in the study. The study was conducted in accordance with 
the Declaration of Helsinki and the applicable laws and 
  regulations of the study countries and regions, and was 
confirmed to be noninterventional by ethical review boards 
in each study country and region.
study population
Patients included in this study were male or female   outpatients 
(day hospitalization allowed) who met the DSM-IV or 
DSM-IV TR diagnostic criteria for   schizophrenia.19 Patients 
were aged between 18 and 65 years and in the 24 months 
before study entry they had had at least two episodes that 
required hospitalization, an increase in the level of care 
(ie, the addition of, or change to, a day hospital program, 
outpatient crisis management, or short-term psychiatric 
treatment in an emergency room), or a change in medication 
regimen (ie, an increase in medication dose, or the addition 
of, or switch to, another medication). In addition, patients 
included in this study required a switch/change to their 
  prim  ary antipsychotic medication (defined as a switch to 
another antipsychotic of the same or different class, a change 
in antipsychotic formulation, or the addition of another 
antipsychotic at a therapeutic dose) because of a physician-
perceived risk of nonadherence. Physicians assessed each 
patient’s risk of nonadherence based on their best clinical 
judgment, and were asked to select a reason for the patient’s 
risk of nonadherence from the following: lack of insight, a 
negative drug attitude, a documented history of medication 
nonadherence, an inadequate response to the primary antipsy-
chotic medication, or intolerance to the primary antipsychotic 
medication.
Patients were excluded if they were considered by the 
physician to be treatment-resistant, or were receiving clozap-
ine because of treatment resistance at study screening; were 
pregnant or nursing; or had an acute, serious, or unstable 
medical condition.
Treatment
Patients enrolled in the study were not randomized to 
  treatment groups and there was no treatment blinding. 
The treating physician determined all aspects of treatment 
and care of the patient in keeping with their best clinical 
  judgment; treatment decisions were solely at the discretion 
of the physician and the patient, and treatment was prescribed 
according to the usual standard of care. Patients perceived to 
be at risk of nonadherence were switched from their primary 
oral antipsychotic medication to another oral antipsychotic 
medication, or to a depot antipsychotic medication, up to 
90 days before study entry (Day 0).Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Figure 1 Patient disposition.
Patient assessment
Patients were observed for 12 months following   enrolment, and 
were assessed at study entry (Day 0), Month 3, Month 12, and 
if they relapsed or withdrew from the study. Variables 
  collected at study entry were the patient’s   sociodemographics, 
psychiatric illness and treatment history, resource utiliza-
tion, patient-reported medication adherence, illness sever-
ity, attitude to their medication(s), insight into their illness, 
and quality of life. Illness severity and the patient’s insight 
into their illness were assessed by the physician using the 
  Clinical Global Impressions of Severity (CGI-S) scale,20 and 
the abbreviated version of the Scale to Assess Unawareness 
of Mental Disorder (SUMD-A).21 Patient’s attitude to their 
medication(s) was assessed using the self-report, 10-item Drug 
Attitude Inventory (DAI-10) questionnaire.22 Quality of life 
was assessed using the self-reported European Quality of Life 
instrument (EQ-5D),23 and health-related quality of life was 
assessed using the patient-rated, 12-item Short Form health 
survey (SF-12).24 United Kingdom (UK) adult population-
based preferences for the EQ-5D health states were used to 
calculate the EQ-5D utility score,25 as country-level norms 
were not available for the participating countries.
statistical analysis
All patients who provided consent to release information 
and who fulfilled the study entry criteria were included 
in the analyses. To provide a more accurate representa-
tion of patient’s clinical and functional illness profile at 
study entry, analyses of the CGI-S, DAI-10, EQ-5D, and 
SUMD-A scores excluded patients who switched treatment 
more than 7 days before their first study visit and analyses 
of SF-12 scores excluded patients who switched treatment 
more than 28 days before their first study visit.
Patient data were analyzed for all patients, and for patients 
who switched to a depot (depot switch subgroup) or oral 
(oral switch subgroup) antipsychotic at the time point   closest 
to study entry. All data are summarized using means and 
standard deviations for continuous variables and counts and 
percentages for categorical variables. Comparisons between 
the depot and oral switch subgroups were analyzed using 
Student’s t test or the Wilcoxon rank sum test for continuous 
variables and Fisher’s exact test (with or without Monte Carlo 
simulation) for categorical variables. For the comparisons of 
the CGI-S, DAI-10, EQ-5D, SF-12, and SUMD-A scores, 
the standardized mean difference effect size (Cohen’s d) was 
also calculated.26 Statistical significance was set at P , 0.05 
(two-sided test). All statistical analyses were carried out using 
SAS® Version 9.1.3 (SAS, Cary, N.C.).
Results
Patient disposition
Of the patients with schizophrenia (N = 7462) reviewed by 
the study physicians, 15.9% (1187/7462) were considered 
to be at risk of nonadherence (Figure 1). The proportion 
of nonadherent patients was higher in Taiwan (21.5%, 
236/1100) and Australia (19.6%, 250/1275) than in Mexico 
(13.1%, 175/1335) and Romania (14.0%, 526/3752). Of these 
patients, 706 were eligible for study entry; however, 38% 
(268/706) refused to participate.
A total of 406 patients at risk of nonadherence were 
switched from their primary oral antipsychotic medication 
to a depot or other oral antipsychotic within 90 days of 
study entry (Day 0) (Figure 1). Of these patients, 84.5% 
(343/406) had switched antipsychotics within 7 days of 
study entry. Most patients (n = 363) were switched from 
their primary oral antipsychotic medication to another oral 
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Table 1 Antipsychotic switch pattern in the overall patient group 
(n = 406)
Antipsychotic n (%)
Before switcha After switchb
Oral → Depot 40 (9.9)
  First-generation   First-generation 8 (2.0)
  First-generation   second-generation 2 (0.5)
  second-generation   First-generation 12 (3.0)
  second-generation   second-generation 18 (4.4)
Oral → Depot + Oral 3 (0.7)
  second-generation     second-generation +  
second-generation
2 (0.5)
  second-generation     First-generation +  
first-generation
1 (0.2)
Oral → Oral 361 (88.9)
  First-generation   First-generation 24 (5.9)
  First-generation   second-generation 105 (25.9)
  second-generation   First-generation 14 (3.4)
  second-generation   second-generation 218 (53.7)
Oral → Oral + Oral 1 (0.2)
  second-generation     second-generation +  
first-generation
1 (0.2)
Oral + Oral → Oral 1 (0.2)
    First-generation +  
first-generation
  second-generation 1 (0.2)
Notes:  aFirst-generation  oral  antipsychotics  taken  before  switch:  flupentixol, 
haloperidol, levomepromazine, perphenazine, pimozide,sulpiride, thioridazine, 
trifluoperazine,  and  zuclophenthixol.  Second-generation  oral  antipsychotics  taken 
before switch: amisulpride, aripiprazole, clotiapine, clozapine, olanzapine, paliperidone, 
quetiapine, risperidone, ziprasidone, and zotepine; bAntipsychotic switch occurred up 
to 90 days before study entry.
from one   second-generation oral antipsychotic to another 
second-generation oral antipsychotic. Few patients (n = 43) 
were switched to depot antipsychotic medication (Table 1). 
Although depot use was low in all countries and regions, 
Mexico had the highest proportion of patients who switched 
to depot (35%) and Taiwan had the lowest proportion (0.7%) 
(Figure 1). Country- and region-specific differences in the 
proportion of patients from each country and region who 
were switched to a depot or oral antipsychotic were observed 
(P , 0.001) (Table 2).
reasons for nonadherence
More than half of the overall patient group was considered 
at risk of nonadherence by their physicians because of 
an   inadequate response to their antipsychotic medication 
(Figure 2). Negative drug attitude and intolerance to drug 
were the next commonly cited reasons, followed by a 
documented history of medication nonadherence and lack 
of insight.
The proportion of each physician-perceived reason for 
nonadherence differed between the depot and oral switch 
subgroups (P , 0.001). Patients in the oral switch subgroup 
were predominantly considered at risk of nonadherence 
because of an inadequate response to their antipsychotic 
medication (57.6%, 209/363). Patients in the depot switch 
subgroup were predominantly considered at risk because 
of an inadequate response to their antipsychotic medica-
tion (34.9%, 15/43) or a documented history of medication 
nonadherence (32.6%, 14/43).
sociodemographic characteristics
Overall, patients tended to be in their late 30s and male 
(Table 2). Most patients had never married or were not in 
a relationship (59.6%), lived with their family (82.0%), 
were unemployed (43.4%), and were not receiving an 
income (54.6%). About 26% of patients had consumed 
alcohol and less than 10% had taken illicit drugs in the 
6 months before study entry. Nearly 70% of patients con-
sidered themselves to be adherent (ie, reported they took 
all their medication or only missed taking their medication 
a couple of times).
In general, the sociodemographic characteristics of 
patients in the depot and oral switch subgroups were similar 
(Table 2). The subgroups were similar in terms of age, sex, 
body mass index, relationship status, living arrangements, 
or income status. Although a higher proportion of patients 
in the oral switch subgroup were employed (32.8%) than 
in the depot switch subgroup (18.6%), no significant dif-
ferences in work status (employed, unemployed, or other) 
were observed between the subgroups. During the 6 months 
before study entry, a significantly higher proportion of 
patients in the depot switch subgroup consumed alcohol 
(P , 0.001) or used illicit drugs (P = 0.010) than patients 
in the oral switch subgroup. Up to 70% of patients in the 
oral switch subgroup and up to 60% of patients in the depot 
switch subgroup considered themselves to be adherent to 
their medication.
Medical and treatment history
In general, patients had their first episode of schizophrenia 
in their mid 20s, and had three episodes or exacerbations of 
schizophrenia and had been hospitalized once, on average, in 
the 24 months before study entry (Table 3). In the 12 months 
before study entry, patients had an average of 11 outpatient 
visits. In terms of treatment history, about 60% of patients had 
been treated with antipsychotics, or anxiolytics, sedatives, 
and hypnotics, 21% had been treated with antidepressants, 
and 29% had been treated with mood stabilizers during the 
12 months before study entry.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Although the illness history of both subgroups was 
somewhat similar, their treatment history before study entry 
differed (Table 3). Patients in the depot switch subgroup had 
their first episode of schizophrenia at a significantly younger 
age than patients in the oral switch subgroup (P = 0.006). 
In the 12 months before study entry, a significantly higher 
proportion of patients in the depot switch subgroup had been 
treated with depot antipsychotics (P = 0.030) than those 
in the oral switch subgroup. In terms of other psychiatric 
medications, a higher proportion of patients in the oral switch 
subgroup had been treated with anxiolytics, sedatives, and 
hypnotics (P = 0.002), whereas a higher proportion of patients 
in the depot switch subgroup had been treated with mood 
stabilizers (P = 0.008).
Clinical and functional illness profile
Overall, patients rated their attitude to their antipsychotic 
medication as slightly positive (DAI-10 score), and their 
quality of life and level of functioning as low (EQ-5D and 
SF-12 scores) (Table 4). In addition, patients were considered 
to be moderately ill (CGI-S score), and were moderately 
aware of their illness (SUMD-A score).
Although there was no significant difference in   illness 
severity (CGI-S score) between patients in the depot and 
oral switch subgroups, significant differences in the mean 
DAI-10, SUMD-A, and EQ-5D utility scores were observed 
between the subgroups (Table 4). Patients in the depot switch 
subgroup reported a significantly less positive attitude to their 
antipsychotic medication than patients in the oral switch 
subgroup (DAI-10 score; P = 0.004). The effect size for this 
difference (0.53) was medium. This less positive attitude 
was characterized by a diminished belief in the statement 
‘for me, the good things about my current medication out-
weigh the bad’ (depot = 57.1%, 20/35, versus oral = 77.5%, 
238/307; P = 0.012) and increased belief in the statements 
‘I take medications only when I am sick’ (depot = 62.9%, 
22/35, versus oral = 29.6%, 91/307; P , 0.001) and ‘it 
is unnatural for my mind and body to be controlled by 
Table 2 Patient sociodemographic characteristics at study entry
Variable Overall 
(N = 406)
Switch subgroups
Depot 
(n = 43)
Oral 
(n = 363)
Pa
Age (years), mean (sD) 37.2 (10.2) 35.8 (12.1) 37.4 (10.0) 0.339
Male, n (%) 230 (56.7) 28 (65.1) 202 (55.6) 0.258
BMi (kg/m2)b, mean (sD) 26.1 (5.56) 27.3 (6.08) 26.0 (5.48) 0.139
country/region, n (%)
  Australia 64 (15.8) 12 (27.9) 52 (14.3) ,0.001
  Mexico 40 (9.9) 14 (32.6) 26 (7.2)
  romania 156 (38.4) 16 (37.2) 140 (38.6)
  Taiwan 146 (36.0) 1 (2.3) 145 (39.9)
relationship status, n (%)
  in relationship  116 (28.6) 9 (20.9) 107 (29.5) 0.485
  Previous relationship 48 (11.8) 5 (11.6) 43 (11.9)
  no relationship 242 (59.6) 29 (67.4) 213 (58.7)
Living arrangements, n (%)
  independent 59 (14.5) 8 (18.6) 51 (14.1) 0.496
  supervised 14 (3.5) 2 (4.65) 12 (3.3)
  Family 333 (82.0) 33 (76.7) 300 (82.6)
Work status, n (%)
  employed 127 (31.3) 8 (18.6) 119 (32.8) 0.151
  Unemployed 176 (43.4) 22 (51.2) 154 (42.4)
  Other 103 (25.4) 13 (30.2) 90 (24.8)
receiving incomec, n (%) 183 (45.4) 17 (40.5) 166 (46.0) 0.518
consumed alcohold, n (%) 105 (25.9) 21 (48.8) 84 (23.2) ,0.001
Used illicit drugsd, n (%) 25 (6.2) 7 (16.3) 18 (5.0) 0.010
Patient-reported adherence to medication, n (%)
  Took all or almost all  278 (68.5) 25 (58.1) 253 (69.7) 0.207
  Took at least half 74 (18.2) 9 (20.9) 65 (17.9)
  Took less than half or stopped altogether 54 (13.3) 9 (20.9) 45 (12.4)
Notes: aDepot versus oral switch subgroup (student’s t test for continuous variables or Fisher’s exact test for categorical variables); bOverall, n = 383; depot, n = 41; oral, 
n = 342; cOverall, n = 403; depot, n = 42; oral, n = 361; din the 6 months before study entry; overall, n = 405; depot, n = 43; oral, n = 362.
Abbreviations: BMi, body mass index; sD, standard deviation.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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  medications’ (depot = 77.1%, 27/35, versus oral = 52.3%, 
161/308; P = 0.007).
Patients in the depot switch subgroup had a significantly 
poorer awareness of their illness than patients in the oral 
switch subgroup (SUMD-A score; P = 0.041) and the effect 
size was small (0.38). This overall poorer awareness was 
characterized by significant differences in the SUMD-A 
variables ‘awareness of mental disorder’ (depot = 2.9 ± 1.2 
18
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Figure 2 Physician-perceived reasons for patients at risk of nonadherence at study entry. The proportion of each physician-perceived reason for nonadherence in each 
subgroup differed (P , 0.001) between the oral and depot switch subgroups (Fisher’s exact test, Monte carlo simulation).
Table 3 Patient medical and treatment history at study entry
Variable Overall 
(N = 406)
Switch subgroups
Depot 
(n = 43)
Oral 
(n = 363)
Pa
Age of first episode (years), mean (SD) 25.7 (8.3) 22.4 (6.9) 26.0 (8.3) 0.006
no. of previous episodes or exacerbationsb, median (range) 2.0 (1.9) 2.0 (0.3) 2.0 (0.3) 0.911
no. of hospitalizationsb, mean (sD) 1.1 (1.5) 1.1 (1.2) 1.1 (1.5) 0.910
no. of outpatient visitsd, mean (sD) 11.1 (9.9) 10.9 (8.5) 11.1 (10.1) 0.920
Antipsychotic medication use in the 12 months before study entrye, n (%)
Overall 172 (58.3) 17 (58.6) 155 (58.3) 1.000
  Oral 153 (51.9) 15 (51.7) 138 (51.9) 1.000
    First-generation 77 (26.1) 4 (13.8) 73 (27.4) 0.125
    second-generation 80 (27.1) 12 (41.4) 68 (25.6) 0.080
  Depot  26 (8.8) 6 (20.7) 20 (7.5) 0.030
    First-generation 15 (5.1) 5 (17.2) 10 (3.8) 0.010
    second-generation  12 (4.1) 2 (6.9) 10 (3.8) 0.334
Other psychiatric medication use in the 12 months before study entryd, n (%)
Overall 261 (88.5) 24 (82.8) 237 (89.1) 0.353
  Antidepressants 62 (21.0) 5 (17.2) 57 (21.4) 0.811
  Anxiolytics, sedatives, hypnotics 185 (62.7) 10 (34.5) 175 (65.8) 0.002
  Mood stabilizers 85 (28.8) 15 (51.7) 70 (26.3) 0.008
Notes: aDepot versus oral switch subgroup (student’s t test for continuous variables or Fisher’s exact test for categorical variables); bin the 24 months before study entry; 
cDepot versus oral switch subgroup (Wilcoxon rank sum test); din the 12 months before study entry; overall, n = 369; depot, n = 41; oral, n = 328; eOverall, n = 295; depot, 
n = 29; oral, n = 266.
Abbreviation: sD, standard deviation.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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versus oral = 2.3 ± 1.3; P = 0.024) and ‘awareness of the 
social consequences of mental disorder’ (depot = 3.0 ± 1.4 
versus oral =  2.4 ± 1.2; P = 0.014).
The mean EQ-5D utility scores indicated that patients 
in the depot switch subgroup rated their quality of life 
  significantly lower (P = 0.013) than patients in the oral switch 
subgroup (Table 4). The effect size for this difference was 
medium (0.44). This lower quality of life was characterized 
by significant differences in the EQ-5D variables mobility 
(P = 0.024) and self-care (P = 0.034). Although the mean 
EQ-5D health state score and the mean SF-12 (physical 
component and mental health) scores were low in both 
  subgroups, these scores did not differ significantly between 
the subgroups (EQ-5D health state, P = 0.341; SF-12 physical 
component, P = 0.687; SF-12 mental health, P = 0.418).
Discussion
This prospective, observational, noninterventional study 
included outpatients with schizophrenia who were deemed 
at risk of relapse secondary to nonadherence. Only a small 
proportion of these patients (10.6%) were switched to depot 
antipsychotics; however, this proportion varied significantly 
among the study countries and regions. Findings from this 
prospective study support and expand previous findings from 
retrospective analyses of depot antipsychotic use.4,16,18 Cur-
rent findings from this analysis suggest that physicians may 
select depot therapy as a treatment option based on   distinct 
patient characteristics including a documented history of 
nonadherence, substance use, early age at illness onset, 
previous use of depot antipsychotics and mood stabilizers, 
poor attitudes towards medications, and poor insight into 
their illness.
The proportion of patients that the study physicians 
initially considered were at risk of nonadherence was low 
(15.9%) compared with the rates reported in a comprehensive 
literature review, which showed that nonadherence rates vary 
from 4% to 72% in patients with schizophrenia.5 The low 
nonadherence rate in this study may be a result of physicians’ 
tendency to overestimate patient adherence to medication,27,28 
as well as the criteria used to define the risk of nonadherence 
in this study. Although these criteria have been validated 
in previous studies,1,5,29 the assessment of the patients’ risk 
was carried out by physicians of different professional and 
cultural backgrounds. Consequently, assessments may have 
differed among and within countries and regions, based 
on differences in the accepted definitions of nonadherence 
between geographical areas. Also, some physicians may have 
defined nonadherence by drug-related factors only, rather 
than using a more inclusive definition encompassing resource 
use, quality of life, and other factors. However, identifying 
patients at risk of nonadherence allows physicians to imple-
ment treatment strategies that may help prevent medication 
nonadherence and its consequences.30
Similar to results from a previous study,31 patients at 
risk of nonadherence in this study were mostly male, in 
their late 30s, living with their family, unemployed, not 
in a   relationship, and had no income. Interestingly, most 
patients also considered themselves to be adherent to their 
antipsychotic medication, despite being considered at risk 
of nonadherence by their physicians. This disparity between 
patient-reported nonadherence and physician-perceived risk 
of nonadherence may be due to patient overestimation or the 
different criteria used by patients versus physicians to mea-
sure nonadherence. While physician-perceived nonadherence 
Table 4 Clinical and functional illness profile at study entrya
Variable Overall 
(N = 343)
Switch subgroups
Depot 
(n = 35)
Oral 
(n = 308)
Effect size Pb
cgi-severity scorec, mean (sD) 4.2 (1.0) 4.0 (0.8) 4.2 (1.0) 0.20 0.245
DAi-10 scored, mean (sD) 2.7 (5.4) 0.2 (5.7) 3.0 (5.3) 0.53 0.004
eQ-5D utility scoree, mean (sD) 0.62 (0.30) 0.50 (0.37) 0.63 (0.29) 0.44 0.013
eQ-5D health state scoref, mean (sD) 56.4 (24.8) 52.5 (30.7) 56.8 (24.1) 0.17 0.341
sF-12 physical component scoreg, h, mean (sD) 44.2 (9.20) 44.7 (9.43) 44.1 (9.18) 0.07 0.687
sF-12 mental health scoreg, h, mean (sD) 35.2 (10.9) 36.5 (12.5) 35.1 (10.7) 0.13 0.418
sUMD-A scorei, mean (sD) 13.0 (4.8) 14.6 (5.5) 12.8 (4.7) 0.38 0.041
Notes: aAnalyses excluded patients who started treatment more than 7 days before their first study visit; bDepot versus oral switch subgroup (student’s t test); c1 is not ill, 
7 is extremely ill; d-10 is negative attitude, 10 is positive attitude (overall, n = 334; oral, n = 299); e1 is perfect health (overall, n = 324; depot n = 33; oral, n = 291); f100 is 
best imaginable health state (overall, n = 337; depot n = 33; oral, n = 304); gAnalyses excluded patients who started treatment more than 28 days before their first study visit 
(patients eligible for assessment, overall, n = 392; depot n = 41; oral,n = 351); h100 is best imaginable health state (overall, n = 391; oral, n = 350); i5 is good awareness, 25 
is poor awareness (overall, n = 328; depot n = 33; oral, n = 295).
Abbreviations: cgi-s, clinical global impressions of severity; DAi, drug attitude inventory; eQ-5D, european quality of life instrument; sD, standard deviation; sF-12, short 
form health survey; sUMD-A, scale to assess unawareness of mental disorder – abbreviated.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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was assessed using the physicians’ best clinical judgment 
rather than via a specific clinical scale or questionnaire, this 
assessment method may more closely reflect actual decisions 
required of physicians in routine clinical practice.
Patients in this study rated their quality of life and level 
of functioning as low, which was similar to the findings from 
the Worldwide-Schizophrenia Outpatient Health Outcomes 
(W-SOHO) study (median EQ-5D health state score = 50; 
interquartile range = 30 to 62), even though patients in that 
study were not selected according to nonadherence risk.13 
Although a negative attitude or poor insight has been asso-
ciated with nonadherence in patients with schizophrenia,5 
patients in this study had a slightly positive attitude towards 
their medication and a moderate awareness of their illness. 
These differences may reflect the low proportion of patients 
(19.7%) in this study who were considered at risk of nonad-
herence because of their attitude to medication and awareness 
of their illness.
The noninterventional and nonrandomized design of this 
study allowed physicians to choose the most   appropriate 
antipsychotic treatment for their patients; however, few 
chose depot antipsychotics despite all enrolled patients being 
considered a nonadherence risk and, therefore, potential can-
didates for depot antipsychotics. This low rate is similar to 
the findings from a retrospective observational study in the 
United States, in which only 12.4% of patients considered 
to be nonadherent with oral antipsychotics were switched to 
depot antipsychotics.4 Given that few patients were switched 
to depot antipsychotics in this study, physician-perceived 
reasons for the risk of nonadherence, rather than the risk of 
nonadherence itself, may have guided the physician to switch 
patients to depot or oral antipsychotics.
Comparable with the baseline findings from the W-SOHO 
study,13 patients in this study switched antipsychotics at 
study entry mainly due to the physician-perceived reason of 
‘inadequate response’, suggesting that physicians perceive 
a lack of drug efficacy as the predominant risk factor for 
nonadherence. Generally, a higher proportion of patients were 
switched to depot antipsychotics because of the physician-
perceived reason ‘documented history of   nonadherence’, 
a result supported by findings in other studies.11,32 These 
results suggest that development of an evaluation tool that 
further helps physicians to objectively assess a patient’s risk 
of nonadherence and appropriateness for depot therapy may 
be beneficial.
Generalizing the study’s findings to individual   populations 
is challenging because of the distinct variability in 
antipsychotic prescribing practices across the study countries 
and regions. Only one of the 146 patients in Taiwan, 
  compared with 14 of the 40 patients in Mexico, was switched 
to depot   antipsychotics. This is not surprising, given the 
many   differences among and within countries and regions 
in terms of treatment guidelines, treatment practices, 
  availability of medications, and the dynamics of the patient-
doctor relationship.33,34 In addition, antipsychotic   prescribing 
practices may also be influenced by country-specific 
  pharmaco-economic considerations, such as the afford-
ability of medications and the cost of administering depot 
antipsychotics and treating potential adverse events.34,35 It is 
not known if cost was a deciding factor in treatment choice 
by patients or physicians in this study. The low use of depot 
antipsychotics in outpatients from Taiwan was surprising, 
particularly given that Taiwan had the highest proportion of 
patients considered to be at risk of nonadherence compared 
with the other study countries. However, findings from the 
W-SOHO study suggest that the use of depot antipsychotics 
is low (6.6%) in the East Asian countries and regions (Korea, 
Malaysia and Taiwan) assessed.13 This low use of depot 
antipsychotics in outpatients may be explained by physician 
preference to prescribe depot antipsychotics to inpatients 
in some countries and regions (for example, it has been 
estimated that 10% to 20% of inpatients in   Taiwan receive 
depot antipsychotics as part of their treatment regimen).12,36 
However, more studies are needed to explore regional varia-
tions in antipsychotic prescription patterns and determine 
specific reasons for regional differences.
Although findings from previous retrospective analyses 
suggested that patients who were male and younger were 
preferentially switched to depot antipsychotics,4,15,16,18 this 
was not evident in our study. However, as our study was 
designed to assess the overall patient population, our ability 
to detect significant differences between subgroups and to 
draw qualitative conclusions for these variables may have 
been limited by the small sample size of the depot switch 
subgroup. Despite this limitation and in agreement with 
previous retrospective analyses, study results showed that 
a significantly higher proportion of patients in the depot 
switch subgroup had consumed alcohol or used illicit drugs 
in the 6 months before study entry.4,16 This is perhaps not 
surprising as substance abuse is a well established risk factor 
for poorer outcomes in patients with schizophrenia.37 In the 
Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) study, for example, illicit drug users were found to 
be less treatment-adherent and were more sick at baseline, 
had less illness course stability, and lived in more stressful 
social environments.37 Other sociodemographic variables Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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associated with depot use, such as a history of involvement 
with the criminal justice system,4 were not assessed in this 
study.
Patients with a distinct previous treatment profile 
may have also been preferentially switched to depot anti-
psychotics. Patients treated with depot antipsychotics in 
the 12 months before study entry were more likely to be 
switched to depot antipsychotics than oral antipsychotics. 
Physicians are more likely to consider prescribing depot 
antipsychotics if their patient has had previous experience 
with depot.18,38 In addition, patient acceptance of depot 
antipsychotics increases with experience,38 and patients 
often prefer to continue taking their current antipsychotic 
formulation, particularly if it is an oral formulation.39 In 
this study, patients may have opted to continue taking oral 
antipsychotic formulations. However, it is not known what 
number of patients refused an offer of a depot antipsychotic 
from their physician. Previous research showed that up to 
35% of patients have refused or would refuse treatment with 
depot antipsychotics.38,40
In addition, a significantly higher proportion of patients 
in the depot switch subgroup had been treated with 
mood stabilizers, and a significantly higher proportion 
of patients in the oral switch subgroup had been treated 
with anxiolytics, sedatives, and hypnotics (consistent with 
  previously reported data)18 in the 12 months before study 
entry. Although the number of multiple comparisons done 
in this study may have increased the probability that some of 
the statistical differences observed may have arisen by chance 
alone, these results may reflect patient factors, eg, patients 
in the oral switch subgroup may be more engaged with the 
treatment team (and more likely to be prescribed anxiolytics, 
  sedatives, and hypnotics). Although depot antipsychotics 
were not indicated for mood disorders at the time this study 
was conducted, patients in the depot switch subgroup may 
have been more aggressive and agitated (and therefore more 
likely to be prescribed mood stabilizers).
Interestingly, patients in the depot and oral switch 
  subgroups had a similar level of illness severity at study 
entry. In a previous study, illness severity (eg, the number 
of   previous hospitalizations) and a more severe treatment 
pattern (eg, recent switching or augmentation of oral 
  antipsychotics) were identified as important drivers for depot 
use in nonadherent patients.4 Given this, the results from this 
study highlight the possibility that physician preference could 
influence treatment decisions. For example, physicians may 
believe that most of their patients are sufficiently adherent 
with oral antipsychotics,41 or that depot antipsychotics are 
less acceptable to patients and are stigmatizing.42,43 Patients 
in the depot switch subgroup had a significantly less   positive 
attitude to their antipsychotic medication and an overall 
poorer awareness of their illness, which may align with a 
patient’s risk of nonadherence. Poor adherence has been 
reported in patients that lack awareness of their illness,44 
and in patients who believe in taking medicine only when 
they are ill, or that taking medicine can cause harm or is 
unnatural,45 beliefs shared by patients in the depot switch 
subgroup of this study.
This is the first prospective study in which the 
  sociodemographic, clinical, and functional characteristics 
of patients considered to be at risk of nonadherence switched 
to either depot or oral antipsychotics were considered. The 
prospective observational design of this study is clinically 
relevant, as the study was conducted in naturalistic settings 
that provided an actual-practice view of the variables that 
may have influenced the switch to depot antipsychotics. 
Although all patients enrolled in this study were considered 
at risk of nonadherence, a key characteristic of patients 
switched to depot antipsychotics was a documented history 
of nonadherence. Other key characteristics included recent 
alcohol or illicit drug use, early age of illness onset, recent 
depot antipsychotic and mood stabilizer use, poor attitudes 
to medications, and a poor awareness of their illness.
Current findings are consistent with previous research,4,16,18 
and show that the patient illness profile may influence a 
physician’s choice of depot over oral antipsychotic therapy. 
Further research is needed, therefore, to better understand 
the assumptions that may drive physicians’ choice of depot 
over oral antipsychotics for only a small proportion of those 
patients who are considered prime candidates for depot 
antipsychotic therapy.
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